168 related articles for article (PubMed ID: 37841851)
1. Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
Res Sq; 2023 Sep; ():. PubMed ID: 37841851
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
Respir Res; 2023 Dec; 24(1):317. PubMed ID: 38104128
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy.
Hilliam Y; Armbruster CR; Rapsinski GJ; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Cooper VS; Lee SE; Bomberger JM
Microbiol Spectr; 2024 Jun; ():e0078724. PubMed ID: 38916354
[TBL] [Abstract][Full Text] [Related]
4. A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung.
Sosinski LM; H CM; Neugebauer KA; Ghuneim LJ; Guzior DV; Castillo-Bahena A; Mielke J; Thomas R; McClelland M; Conrad D; Quinn RA
J Cyst Fibros; 2022 Nov; 21(6):996-1005. PubMed ID: 34824018
[TBL] [Abstract][Full Text] [Related]
5. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.
Fila L; Grandcourtova A; Bilkova A; Drevinek P
Front Pharmacol; 2023; 14():1178009. PubMed ID: 37332357
[No Abstract] [Full Text] [Related]
6. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
Schaupp L; Addante A; Völler M; Fentker K; Kuppe A; Bardua M; Duerr J; Piehler L; Röhmel J; Thee S; Kirchner M; Ziehm M; Lauster D; Haag R; Gradzielski M; Stahl M; Mertins P; Boutin S; Graeber SY; Mall MA
Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37414422
[TBL] [Abstract][Full Text] [Related]
8. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
9. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis.
Zemke AC; Hilliam Y; Stapleton AL; Kimple AJ; Goralski JL; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Cooper VS
Int Forum Allergy Rhinol; 2024 May; 14(5):928-938. PubMed ID: 37837613
[TBL] [Abstract][Full Text] [Related]
10. Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature.
Tupayachi Ortiz MG; Baumlin N; Yoshida M; Salathe M
Heliyon; 2024 Mar; 10(5):e26955. PubMed ID: 38463894
[TBL] [Abstract][Full Text] [Related]
11. Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity.
Schütz K; Pallenberg ST; Kontsendorn J; DeLuca D; Sukdolak C; Minso R; Büttner T; Wetzke M; Dopfer C; Sauer-Heilborn A; Ringshausen FC; Junge S; Tümmler B; Hansen G; Dittrich AM
Front Pharmacol; 2023; 14():1171544. PubMed ID: 37469865
[No Abstract] [Full Text] [Related]
12. Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic Fibrosis.
Sheikh S; Ho ML; Eisner M; Gushue C; Paul G; Holtzlander M; Johnson T; McCoy KS; Lind M
JAMA Otolaryngol Head Neck Surg; 2023 Dec; 149(12):1075-1082. PubMed ID: 37676668
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor.
Gruber W; Stehling F; Blosch C; Dillenhoefer S; Olivier M; Brinkmann F; Koerner-Rettberg C; Sutharsan S; Mellies U; Taube C; Welsner M
Front Sports Act Living; 2024; 6():1284878. PubMed ID: 38463712
[TBL] [Abstract][Full Text] [Related]
14. Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the
Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Ferrillo L; Pepe A; Francalanci M; Taccetti G; Buonaurio S; Celardo A; Salvadori L; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207295
[TBL] [Abstract][Full Text] [Related]
15. Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.
Cavinato L; Luly FR; Pastore V; Chiappetta D; Sangiorgi G; Ferrara E; Baiocchi P; Mandarello G; Cimino G; Del Porto P; Ascenzioni F
Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 36455959
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
[TBL] [Abstract][Full Text] [Related]
17. Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.
McNally P; Lester K; Stone G; Elnazir B; Williamson M; Cox D; Linnane B; Kirwan L; Rea D; O'Regan P; Semple T; Saunders C; Tiddens HAWM; McKone E; Davies JC;
Am J Respir Crit Care Med; 2023 Nov; 208(9):917-929. PubMed ID: 37703083
[No Abstract] [Full Text] [Related]
18. Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.
Gushue C; Eisner M; Bai S; Johnson T; Holtzlander M; McCoy K; Sheikh S
Pediatr Pulmonol; 2023 Aug; 58(8):2308-2316. PubMed ID: 37222417
[TBL] [Abstract][Full Text] [Related]
19. Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis.
Casey M; Gabillard-Lefort C; McElvaney OF; McElvaney OJ; Carroll T; Heeney RC; Gunaratnam C; Reeves EP; Murphy MP; McElvaney NG
Thorax; 2023 Aug; 78(8):835-839. PubMed ID: 37208188
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
Nichols DP; Morgan SJ; Skalland M; Vo AT; Van Dalfsen JM; Singh SB; Ni W; Hoffman LR; McGeer K; Heltshe SL; Clancy JP; Rowe SM; Jorth P; Singh PK;
J Clin Invest; 2023 May; 133(10):. PubMed ID: 36976651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
